A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium

Multiple-system atrophy is a neurologic disorder characterized by orthostatic hypotension, Parkinsonian signs, and cerebellar signs. Mutations in COQ2, an enzyme involved in coenzyme Q10 (CoQ10) synthesis were recently associated with familial and sporadic cases of multiple-system atrophy. I hypothesized that people with symptoms suggesting multiple-system atrophy might benefit from CoQ10 administration. Five patients with symptomatic orthostatic hypotension were treated in an unrandomized manner with 240±40 mg CoQ10 daily for 8±3 months - two had Parkinsonian and one had cerebellar signs. Prior to starting CoQ10, systolic BP fell 30±5 mmHg upon standing from a sitting position. After treatment with CoQ10, systolic BP fell 8±5 mmHg upon standing from a sitting position (p=0.013 for change in systolic BP fall by paired t test). These data suggest that orthostatic hypotension could possibly improve with CoQ10 administration and that a randomized clinical trial to test this hypothesis should be begun.

Download Full-text

Effects of coenzyme Q10 supplementation on oxidative stress and antioxidant enzyme activity in glazers with occupational cadmium exposure: A randomized, double-blind, placebo-controlled crossover clinical trial

Toxicology and Industrial Health ◽

10.1177/0748233718809256 ◽

2018 ◽

Vol 35 (1) ◽

pp. 32-42 ◽

Cited By ~ 1

Author(s):

Maryam Hormozi ◽

Ramazan Mirzaei ◽

Alireza Nakhaee ◽

Abolfazl payandeh ◽

Shahrokh Izadi ◽

...

Keyword(s):

Oxidative Stress ◽

Clinical Trial ◽

Antioxidant Enzymes ◽

Coenzyme Q10 ◽

Dietary Intervention ◽

Oxidative Stress Marker ◽

Double Blind ◽

Double Blind Placebo ◽

Enzymes Activity ◽

Coenzyme Q10 Supplementation

Recently, there is a growing interest for the use of antioxidants as a preventive agent against cadmium (Cd) intoxication. The current study aimed to investigate the effects of dietary coenzyme Q10 supplementation on oxidative stress and antioxidant enzymes activity in Cd-exposed glazers. In a randomized, double-blind, placebo-controlled 2-month crossover clinical trial, coenzyme Q10 (60 mg twice daily) or placebo was administrated to 40 male glazers occupationally exposed to Cd. The subjects were randomly assigned to the placebo and coenzyme Q10 groups ( n = 20 in each group). Total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) as well as malondialdehyde (MDA) in the serum of glazers were measured at baseline and at the end of both intervention phases. The primary outcomes were the changes in serum levels of MDA, TAC and the activities of SOD, CAT, and GPx during administration with coenzyme Q10 versus placebo. Compared with placebo, treatment to coenzyme Q10 was associated with a significant reduction in serum MDA levels ( p < 0.001) While, there was no significant effect on the serum TAC levels ( p = 0.096). Also, the activity antioxidant enzymes of SOD ( p < 0.001) and GPx ( p = 0.003) were significantly higher and the CAT activity ( p < 0.001) was lower after 2-month coenzyme Q10 administration compared with placebo. Data demonstrated that coenzyme Q10 supplementation at a dose of 60 mg (twice daily) is effective in reducing oxidative stress marker level (MDA) and improving antioxidant enzymes activity in glazers exposed to Cd. However, further research is needed to assess coenzyme Q10 as a possible dietary intervention in Cd-exposed workers. Trial Registration: Iranian Registry of Clinical Trials Registration Number: IRCT2016061228407N1 ( www.who.int/ictrp/network/irct/en/ ).

Download Full-text